FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization (Updated 2026)
CONCEPTFDA's TEMPO (Total Product Life Cycle Advisory Program) pilot represents an innovative regulatory approach allowing generative AI medical devices to reach patients before full pre-market authorization, with post-market surveillance and evidence collection. This pathway accelerates patient access to AI devices while maintaining safety oversight through continuous monitoring and evidence generation. It represents a shift from traditional pre-market validation toward adaptive post-market evaluation. The TEMPO approach reflects FDA recognition that traditional pre-market evidence standards may be inappropriate for AI systems that improve continuously and adapt to new clinical contexts. --- ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.